Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development Genialis, the RNA biomarker company, today announced an ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues in the human body. Now researchers have developed a method to detect ...

The challenges encountered by proteomic researchers seeking diagnostic, prognostic and mechanistic markers were the subject of the 1-day meeting, Proteomics: Advances in Biomarker Discovery hosted ...

The FSR Pilot Grant program, initiated in 2018, seeks to fund innovative research in both clinical and basic science settings ...

According to Future Market Insights’ updated report, the renal biomarker market is projected to experience steady growth over ...

Tests to identify such signs in infants could ultimately help save lives, the researchers say. "Our study is the largest study to date that has attempted to detect how these small molecules in the ...

The global neurological biomarkers market is set to experience significant expansion in the coming years, driven by a growing demand for accurate diagnostic tools and advanced treatment monitoring ...

NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to ...